Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - alendronic acid - tablets - 10 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg) - tablet - excipient ingredients: povidone; croscarmellose sodium; lactose monohydrate; magnesium stearate; microcrystalline cellulose - fonat is indicated for the treatment of: osteoporosis, including glucocorticoid-induced osteoporosis. fonat is indicated for the prevention of glucocorticoid-induced osteoporosis in those patients on long term corticosteroid therapy (see clinical trials, glucorticoid-induced osteoporosis). prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the mean for young adults (gender specific), or by: - the presence of osteoporotic fracture.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - alendronate sodium, quantity: 10.884 mg (equivalent: alendronic acid, qty 10 mg) - tablet, uncoated - excipient ingredients: mannitol; croscarmellose sodium; purified talc; colloidal anhydrous silica; magnesium stearate - *for the treatment of osteoporosis. osteoporosis must be confirmed by: the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by the presence of osteoporotic fracture. * treatment and prevention of glucocorticoid-induced osteoporosis in post menopausal women not receiving oestrogen and who are on long term corticosteroid therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - alendronate sodium trihydrate, quantity: 91.35 mg (equivalent: alendronic acid, qty 70 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; mannitol - treatment of osteoporosis. osteoporosis must be confirmed by the finding of low bone mass of at least two standard deviations below the gender specific mean for young adults, or by the presence of osteoporotic fracture.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - alendronic acid as trihydrate - tablets effervescent - alendronic acid as trihydrate 70 mg - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures).treatment to increase bone mass in men with osteoporosis

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الأردنية السويدية - jordan sweden medical & sterilization co. - alendronate sodium eq to alendronic acid 70 mg - eq to alendronic acid 70 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - alendronate sodium, quantity: 91.363 mg (equivalent: alendronic acid, qty 70 mg) - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; maize starch; microcrystalline cellulose; magnesium stearate - for the treatment of osteoporosis. osteoporosis must be confirmed by the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults, or by the presence of osteoporotic fracture.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - alendronate sodium monohydrate, quantity: 81.24 mg (equivalent: alendronic acid, qty 70 mg) - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; magnesium stearate - treatment of osteoporosis, including glucocorticoid induced osteoporosis. osteoporosis must be confirmed by the finding of low bone mass of at least two standard deviations below the gender specific mean for young adults or by the presence of history of osteoporotic fracture. paget's disease of bone.

European Union - English - EMA (European Medicines Agency)

n.v. organon - alendronic acid, colecalciferol - osteoporosis, postmenopausal - drugs for treatment of bone diseases - treatment of postmenopausal osteoporosis in patients at risk of vitamin-d insufficiency.fosavance reduces the risk of vertebral and hip fractures.

European Union - English - EMA (European Medicines Agency)

n.v. organon - alendronic acid, colecalciferol - osteoporosis, postmenopausal - drugs for treatment of bone diseases - treatment of postmenopausal osteoporosis in patients at risk of vitamin-d insufficiency.vantavo reduces the risk of vertebral and hip fractures.treatment of postmenopausal osteoporosis in patients who are not receiving vitamin-d supplementation and are at risk of vitamin-d insufficiency.vantavo reduces the risk of vertebral and hip fractures.